Heineken has warned UK pubs that the rise of weight-loss drugs could reduce beer sales, advising venues to promote smaller serves and low-alcohol options.
New research from Rutgers University identifies a small increase in the risk of ischemic optic neuropathy among patients taking GLP-1 medications like Ozempic and Wegovy.
A multinational study finds that GLP-1 weight loss drugs are linked to significantly higher rates of nail detachment and hair loss, though researchers say the changes are usually benign.
The World Health Organization has issued new guidelines advising against the use of obesity drugs for children under 10, prioritizing lifestyle changes over medication.
